GLAXOSMITHKLINE UK LIMITED

Active
Company number 04310159Private limited companyIncorporated 2001

Key figures

£778,970,000
Net assets 2024

† GLAXOSMITHKLINE UK LIMITED filed these accounts on paper, so Companies House publishes them only as a scanned image. The figures for the years marked † were read automatically from the scan and kept only where the statements add up (for example net assets equal total equity), but a reading error is still possible — check the original accounts at Companies House.

Ratios

2024

Sector comparison

SIC 46460

Where the company stands among the 2,974 active companies whose first SIC code is 46460 (Wholesale of pharmaceutical goods).

Turnover£596,571,000
Higher than 95% · median £23,764,000 among 214 that publish turnover
Net assets£778,970,000
Higher than 99% · median £32,520
Total assets£945,136,000
Higher than 99% · median £255,000
Employees445
Higher than 99% · median 1
Company age25.0 years
Older than 87% · median 6.2 years
Largest in this sector by net assets
  1. CSL BEHRING HOLDINGS LIMITED£11bn
  2. VIIV HEALTHCARE UK LIMITED£5.7bn
  3. MCKESSON GLOBAL SOURCING LIMITED£1bn
  4. MCKESSON MEDICAL-SURGICAL SOURCING LIMITED£999.5m
  5. PFIZER LIMITED£984m
  6. ABBOTT LABORATORIES LIMITED£871.8m
  7. GLAXOSMITHKLINE UK LIMITED£779m
  8. UNIKERIS LIMITED£642m
  9. HALEON UK TRADING LIMITED£554.8m
  10. MUNDIPHARMA MEDICAL COMPANY LIMITED£461.7m

Positions are approximate. Figures come from each company's latest accounts; money and employee figures are compared only with companies that filed accounts in pounds for a period ending in the last two and a half years and are not dormant, so those groups are smaller than 2,974. The line on each bar marks the median.

Summary: GLAXOSMITHKLINE UK LIMITED

What kind of company is it?

GLAXOSMITHKLINE UK LIMITED is a private limited company registered with Companies House under company number 04310159. It was incorporated on 24 Oct 2001. Its status is active. The registered office is in London (WC1A). Its nature of business (SIC 2007) is wholesale of pharmaceutical goods (46460).

How is the company doing financially?

The latest accounts in the database are for 2024 (period ending 31 Dec 2024); the company files full accounts. Turnover was £596,571,000. Profit for the year was £42,659,000. Net assets were £778,970,000. Total assets were £945,136,000 and total liabilities £166,166,000. The company had an average of 445 employees.

How does it compare with similar companies?

Compared with 2,974 active companies whose first SIC code is 46460: By turnover it ranks higher than 95% of the 214 that publish turnover (median £23,764,000). By net assets it ranks higher than 99% of them (median £32,520). By total assets it ranks higher than 99% of them (median £255,000). By number of employees it ranks higher than 99% of them (median 1). It is older than 87% of them (median age 6.2 years).

Does it supply the public sector?

The company is named as a supplier in 70 public contract award notices from 10 public sector buyers since 2015. Contracts awarded to it alone have a combined published value of £665.5m. Its most frequent buyer is NHS England (31 contracts). 24 of the awards are shared with other suppliers, typically framework agreements.

What do public registers and reports show?

In its latest payment practices report it took an average of 41 days to pay suppliers, and 2% of invoices were not paid within agreed terms. It has modern slavery statements on the government registry for 6 years.

Who runs and controls the company?

One person with significant control is registered.

When are its next filings due?

The next accounts are due by 30 Sep 2027. The next confirmation statement is due by 15 Jun 2027.

Filed accounts2024
2024 †
Turnover596,571,000
Profit for the year42,659,000
Total assets945,136,000
Total liabilities166,166,000
Net assets / total equity778,970,000
Average number of employees445

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Public contracts

70 contracts

GLAXOSMITHKLINE UK LIMITED is named as a supplier in 70 public contract award notices from 10 public sector buyers since 2015. The 5 contracts awarded to it alone with a published value add up to £665.5m. 24 awards are shared with other suppliers and not counted in that total.

Contracts per year
Main buyers10
NHS England
31 contracts
DEPARTMENT OF HEALTH
8 contracts
COMMERCIAL MEDICINES UNIT
7 contracts
Secretary of State for Health and Social Care acting as part of the Crown through UK Heal…
6 contracts
Department of Health and Social Care (DHSC)
4 contracts · £597.3m
Contracts
  1. NHS National Generic Pharmaceuticals - Wave 16a‡NHS England · shared by 101 suppliers, up to £393,331,872 in total · runs until Jan 2029
  2. NHS Branded Medicines Tranche A - NOFE and Midlands & East and Natalizumab for London & SOFE - 1 September 2026‡NHS England · shared by 25 suppliers, up to £1,330,779,176 in total · 2 lots · runs until Aug 2028
  3. Generic, Branded Generic & Proprietary Medicinal Products - Group 18‡Regional Business Services Organisation, Procurement and Logistics Service · £2,003,241
  4. NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026‡NHS England · shared by 25 suppliers, up to £1,627,727,168 in total · 2 lots · runs until Aug 2028
  5. Meningitis B Vaccine (2026)‡Secretary of State for Health and Social Care acting as part of the Crown through UK Heal… · £2 · 2 lots · runs until Sep 2029
Show 65 more
  1. Herpes zoster, inactivated vaccine (2027)‡Secretary of State for Health and Social Care acting as part of the Crown through UK Heal… · runs until Mar 2029
  2. NHS National Generic Pharmaceuticals - Wave 15c‡NHS England · shared by 104 suppliers, up to £403,702,000 in total · runs until May 2028
  3. Measles, Mumps, Rubella and Varicella (MMRV) vaccine (2025)‡Secretary of State for Health and Social Care acting as part of the Crown through UK Heal… · £1
  4. NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025‡NHS England · shared by 21 suppliers, up to £986,282,758 in total · runs until Aug 2027
  5. NHS Framework Agreement for Branded Medicines – Tranche B - NOFE & MAE and Eculizumab & Ravulizumab for London & SOFE - 01 September 2025‡NHS England · £1
  6. NHS Branded Medicines Tranche A - London & SOFE & Adult Influenza National‡NHS England · shared by 28 suppliers, up to £261,895,933 in total · runs until Aug 2027
  7. NHS Framework Agreement for Branded Medicines – Tranche A London and South of England and Adult Influenza (National) - 01 September 2025‡NHS England · £1
  8. NHS National Generic Pharmaceuticals Wave 15b‡NHS England · £1
  9. Rotavirus vaccine (2025)‡Secretary of State for Health and Social Care acting as part of the Crown through UK Heal… · £1
  10. NHS National Generic Pharmaceuticals Wave 15a‡NHS England · £2 · 2 lots
  11. NHS Branded Medicines Tranche Framework for London and South of England‡NHS England · £2 · 2 lots
  12. DTaP/IPV/Hib+HepB vaccine (2025)‡UK Health Security Agency · £1 · runs until Mar 2029
  13. DTaP/IPV/Hib+HepB vaccine (2025)‡Secretary of State for Health and Social Care acting as part of the Crown through UK Heal… · £1
  14. NHS Framework Agreement for Branded Medicines - National Tender - 1 May 2024‡NHS England · £1
  15. NHS National Generic Pharmaceuticals Wave 14c (CF Award - Part 1)‡NHS England · shared by 63 suppliers, up to £1 in total · runs until May 2027
  16. NHS National Generic Pharmaceuticals Wave 14c‡NHS England · £2 · 2 lots
  17. NHS Branded Medicines Framework for North of England and Midlands and East - 1 March 2024‡NHS England · £2 · 2 lots
  18. NHS South of England Branded Medicines - Tranche A - September 2023‡NHS England · £1
  19. NHS London Branded Medicines - Tranche B - September 2023‡NHS England · £1
  20. NHS National Generic Pharmaceuticals Wave 14b‡ATAMIS LTD · shared by 99 suppliers, up to £428,226,984 in total
  21. NHS National Generic Pharmaceuticals Wave 14b‡NHS England · £2 · 2 lots
  22. NHS North of England Branded Medicines Tranche A & Annual Tranche‡NHS England · £1
  23. NHS Midland & East Branded Medicines, Tranche B & Annual Tranche‡NHS England · shared by 35 suppliers, up to £480,429,000 in total
  24. NHS Framework for Midland & East Branded Medicines, Tranche B & Annual Tranche‡NHS England · £1
  25. NHS Framework for North of England Branded Medicines Tranche A & Annual Tranche‡NHS England · shared by 29 suppliers, up to £261,970,000 in total
  26. NHS National Generic Pharmaceuticals Wave 14a‡NHS England · £1
  27. Contract for the supply of meningococcal group B vaccine (2022)‡UK Health Security Agency · £1
  28. Meningococcal group B vaccine (2022)‡Secretary of State for Health and Social Care acting as part of the Crown through UK Heal… · £1
  29. NHS Framework Agreement for South of England Branded - Tranche B and Annual‡NHS England · £1
  30. NHS Framework Agreement for London, Branded Medicines - Tranche A and Annual‡NHS England · £1
  31. NHS Framework Agreement for Branded medicines - National‡NHS England · shared by 86 suppliers, up to £526,000,000 in total
  32. NHS Framework Agreement for Branded Medicines - National Tender‡NHS England · £1
  33. NHS Framework for Midlands and East, Branded Medicines - Tranche A and Annual‡NHS England · shared by 31 suppliers, up to £216,078,796 in total
  34. NHS Framework for the North of England, Branded Medicine‡NHS England · shared by 31 suppliers, up to £716,741,676 in total · 3 lots
  35. NHS Framework for the North of England, Branded Medicine‡The NHS Commissioning Board (operating under the name of NHS England) · £1
  36. NHS Framework for Midlands and East, Branded Medicines – Tranche A and Annual‡The NHS Commissioning Board (operating under the name of NHS England) · £1
  37. NHS National Generic Pharmaceuticals Wave 13‡ATAMIS LTD · shared by 100 suppliers, up to £939,483,068 in total · 2 lots
  38. NHS National Generic Pharmaceuticals Wave 13‡ATAMIS LTD · shared by 99 suppliers, up to £469,741,550 in total
  39. NHS National Generic Pharmaceuticals Wave 13‡The NHS Commissioning Board (operating under the name of NHS England) · £2 · 2 lots
  40. VIR-7831 Supply Agreement for Pandemic Purposes‡Department of Health and Social Care · £5
  41. NHS National Generic Pharmaceuticals Interim 2‡NHS England · shared by 51 suppliers, up to £12,327,097 in total
  42. NHS National Generic Pharmaceuticals Interim 2 2020‡The NHS Commissioning Board (operating under the name of NHS England) · £1
  43. Contract for supply of herpes zoster (shingles) vaccine(recombinant, adjuvanted)‡Department of Health and Social Care (DHSC) · £66,131,483
  44. Contract for supply of herpes zoster (shingles) vaccine(recombinant, adjuvanted)‡Department of Health and Social Care · £66,131,483
  45. Contract for the supply of DTaP/IPV/Hib+HepB‡Department of Health and Social Care (DHSC) · shared by 2 suppliers, up to £178,628,670 in total
  46. Contract for the Supply of rotavirus vaccine‡Department of Health and Social Care (DHSC) · £448,000,000 · 2 lots
  47. Covid-19 Flu Vaccine Buffer Stock‡Department of Health and Social Care (DHSC) · £83,209,000 · 5 lots
  48. Contract for supply of Hib-Men C vaccineDepartment of Health and Social Care
  49. Contract for the supply of Meales, Mumps and Rubella (MMR) vaccineDEPARTMENT OF HEALTH · shared by 2 suppliers
  50. Contract for the supply of Diptheria, Tetanus, Pertussis and Polio VaccineDEPARTMENT OF HEALTH
  51. NHS Framework Agreement for Branded Medicines - NationalNHS England · shared by 73 suppliers, up to £1,351,341,890 in total
  52. Contract for the supply of Antibiotics and IV Fluids under a Dynamic Purchasing SystemDEPARTMENT OF HEALTH AND SOCIAL CARE
  53. Contract for the supply of rabies vaccineDepartment of Health
  54. Antivirals for use in an influenza pandemic, or wide scale epidemicDEPARTMENT OF HEALTH
  55. Contract for the supply of meningococcal B vaccineDEPARTMENT OF HEALTH
  56. Contract for the supply of hepatitis A vaccine‡DEPARTMENT OF HEALTH · shared by 2 suppliers
  57. Hepatitis A vaccine‡DEPARTMENT OF HEALTH · shared by 2 suppliers
  58. Dynamic Purchasing System (DPS) for the supply of antibiotics and IV fluids‡COMMERCIAL MEDICINES UNIT · shared by 5 suppliers
  59. NHS framework agreement for supply of seasonal influenza vaccine, for delivery during the 2017/18 flu season‡COMMERCIAL MEDICINES UNIT · shared by 5 suppliers
  60. Contract for the supply of DTaP/IPV/Hib‡COMMERCIAL MEDICINES UNIT
  61. Contract for the supply of rotavirus vaccine‡COMMERCIAL MEDICINES UNIT
  62. Contract for the supply of inactivated vaccine for the children's flu programme‡COMMERCIAL MEDICINES UNIT · shared by 2 suppliers
  63. Contract for the suply of haemophilus influenza type b, meningococcal C vaccine (Hib/Men C)‡COMMERCIAL MEDICINES UNIT
  64. NHS National Framework Agreement for the emergency supply of Generic Pharmaceuticals - Co-Amoxiclav powder for solution (for DLN and DNW Regions only)‡COMMERCIAL MEDICINES UNIT
  65. Contract for the supply of meningococcal B vaccine‡DEPARTMENT OF HEALTH

From contract award notices on Contracts Finder (since 2016) and Find a Tender (since 2021), published by the Cabinet Office under the Open Government Licence v3.0. Values are as published by the buyer and usually cover the whole contract term; the total leaves out awards shared between several suppliers, where the published figure is a ceiling for all of them, placeholder values and single figures of £1 billion or more. Notices marked ‡ do not state a company number and were linked by an exact match on the registered name. Contracts below the publication thresholds and those of devolved buyers that publish elsewhere are not included.

Statutory reporting

Payment practices1 Jan 2026 – 30 Jun 2026
Average time taken to pay invoices
41 days
Invoices not paid within agreed terms
2%
Standard payment terms
0–60 days
  • Within 30 days 37%
  • 31 to 60 days 58%
  • After 60 days 5%
Earlier periods (7)
Period ending
Days to pay
Within 30 days
Late
31 Dec 2025
36
38%
1%
30 Jun 2025
38
31%
2%
31 Dec 2024
45
24%
2%
30 Jun 2024
51
20%
2%
31 Dec 2023
48
26%
4%
30 Jun 2023
47
33%
5%
31 Dec 2022
53
25%
7%

View the latest report on GOV.UK

Modern slavery statements6
2026
Statement · summary on GOV.UK · group statement (GSK PLC)
2025
Statement · summary on GOV.UK · group statement (GSK PLC)
2024
Statement · summary on GOV.UK · group statement (GSK PLC)
Earlier years (3)
2023
Statement · summary on GOV.UK · group statement (GSK PLC)
2022
Statement · summary on GOV.UK · group statement (GSK PLC)
2021
Statement · summary on GOV.UK · group statement (GSK PLC)

Figures the company reported itself to the government's Check payment practices service, Gender pay gap service and Modern slavery statement registry (Open Government Licence v3.0). Only large companies and employers with 250 or more staff have to report, so most companies have nothing here.

History

4 events
  1. Financial year endedAccounts filed at Companies House
  2. Financial year 2024 endedAccounts: turnover £596.6m, net assets £779m, 445 employees
  3. Glaxo Group Limited registered as a person with significant control
  4. Company incorporatedPrivate limited company

Dates as recorded at Companies House: incorporation, name changes, officer appointments and resignations, current persons with significant control, and the end of each financial year with figures in the database. Former persons with significant control are not listed.